Tremfya and Humira are two biologics for moderate-to-severe ulcerative colitis that take fundamentally different mechanistic approaches. Humira is the established anti-TNF with more than a decade of UC experience. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, which uniquely offers both subcutaneous and intravenous induction pathways. UC patients choosing between these drugs weigh mechanism, administration flexibility, and long-term safety. This guide walks through the tremfya vs humira ulcerative colitis decision.
Anti-TNF vs IL-23 p19 Mechanism
Humira (adalimumab) is a fully human monoclonal antibody that binds TNF-alpha and reduces inflammation throughout the body and in the colon. Tremfya (guselkumab) binds the p19 subunit of interleukin-23, selectively blocking only IL-23. IL-23 is central to Th17 inflammation in UC, while leaving IL-12 intact may preserve immune surveillance. The guselkumab vs adalimumab UC distinction shapes efficacy timing, safety profile, and long-term convenience. Humira's broader TNF blockade produces faster systemic anti-inflammatory effects and covers extraintestinal manifestations. Tremfya's narrower IL-23 targeting produces strong efficacy with a cleaner safety profile.
QUASAR and ASTRO: Tremfya UC Evidence
QUASAR was the pivotal phase 3 induction and maintenance trial of guselkumab in UC. The induction trial randomized biologic-naive and biologic-experienced UC patients to IV guselkumab induction or placebo. At week 12, 23% of guselkumab patients achieved clinical remission compared with 8% on placebo, with endoscopic improvement also significantly better. Maintenance through week 44 showed sustained remission in patients who continued guselkumab versus those who switched to placebo. ASTRO specifically evaluated fully subcutaneous induction for guselkumab in UC, demonstrating that patients could skip IV induction entirely and still achieve meaningful response. Humira's UC efficacy rests on ULTRA-1 and ULTRA-2, which established modest but meaningful benefit over placebo.
Efficacy Comparison
No head-to-head trial has compared Tremfya with Humira in UC. Indirect comparisons from network meta-analyses suggest Tremfya produces similar or potentially higher clinical remission rates than Humira in biologic-naive patients. The VARSITY head-to-head trial (Entyvio vs Humira) showed Humira underperforming compared with gut-selective therapy, which has broader implications for how anti-TNFs compare with newer mechanism classes in UC. For anti-TNF experienced patients, Tremfya's p19 selectivity offers a meaningful mechanism switch that typically delivers better outcomes than a second anti-TNF.
Onset of Action
Humira tends to produce early symptom improvement within the first few weeks of induction. Tremfya's UC onset produces meaningful response by week 12 based on QUASAR. For UC patients with severe, active symptoms who need rapid control, Humira's faster action is often preferred. For patients in less acute states, Tremfya's response trajectory is generally acceptable and the unique SC induction option (ASTRO) allows patients to start therapy without infusion center visits.
Safety Profiles
Humira carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Tremfya's UC safety data from QUASAR and ASTRO, along with its extensive psoriasis and psoriatic arthritis experience, has been favorable with lower systemic infection rates than anti-TNFs. For tremfya vs humira side effects, UC patients with infection concerns or cancer history often find Tremfya's narrower mechanism more reassuring. Both drugs require TB and hepatitis B screening before starting, and both can be used as monotherapy.
Administration and Dosing Flexibility
Humira is a subcutaneous injection throughout. UC induction is 160 mg on day 1 and 80 mg on day 15, followed by 40 mg every other week, per AbbVie's prescribing information. Tremfya offers uniquely flexible UC administration. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) based on preference and access, per the QUASAR and ASTRO programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. For UC patients who want all-SC administration, both drugs offer that option. Tremfya's every-8-week SC maintenance is less frequent than Humira's every-other-week cadence.
Cost and Access
Humira faces extensive biosimilar competition. Multiple adalimumab biosimilars are designated interchangeable with Humira, including Amjevita, Cyltezo, Hyrimoz, Abrilada, Hulio, Simlandi, and Yuflyma. Many pharmacy benefit managers prefer biosimilar adalimumab. Tremfya has no biosimilar and is priced as a branded biologic. For UC patients where insurance strongly favors a low-cost adalimumab biosimilar, Humira (or its biosimilar) may be the most accessible option. For patients whose plans cover Tremfya and prioritize the IL-23 mechanism or SC induction flexibility, manufacturer copay assistance programs can help bridge cost gaps.
Choosing With Your GI
For a UC patient deciding between Tremfya and Humira, both drugs offer meaningful response in biologic-naive patients. Humira tends to win on speed of onset, biosimilar cost savings, and coverage of extraintestinal manifestations. Tremfya tends to win on long-term safety, less frequent SC maintenance, and unique SC-only induction that eliminates infusion center visits. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles adalimumab biosimilars versus branded IL-23 biologics. A log of stool frequency, urgency, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.